DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,699,664 | +95.6% | 31,034 | +89.2% | 2.64% | +3.0% |
| Q2 2023 | $3,936,302 | -4.3% | 16,401 | +0.5% | 2.57% | -11.4% |
| Q1 2023 | $4,112,098 | -8.1% | 16,315 | -3.2% | 2.90% | -17.9% |
| Q4 2022 | $4,475,581 | +7.9% | 16,862 | -0.6% | 3.53% | +0.7% |
| Q3 2022 | $4,149,000 | -3.2% | 16,962 | +0.3% | 3.50% | +2.0% |
| Q2 2022 | $4,287,000 | -3.9% | 16,910 | +0.2% | 3.43% | +11.2% |
| Q1 2022 | $4,463,000 | -19.6% | 16,869 | -0.1% | 3.09% | -3.6% |
| Q4 2021 | $5,554,000 | +6.6% | 16,880 | -1.3% | 3.20% | -2.3% |
| Q3 2021 | $5,208,000 | +13.5% | 17,107 | +0.1% | 3.28% | +13.5% |
| Q2 2021 | $4,588,000 | +19.8% | 17,096 | +0.5% | 2.89% | +9.1% |
| Q1 2021 | $3,830,000 | +2.1% | 17,016 | +0.8% | 2.65% | -6.0% |
| Q4 2020 | $3,751,000 | +2.5% | 16,886 | -0.6% | 2.82% | -12.8% |
| Q3 2020 | $3,658,000 | +21.0% | 16,986 | -0.6% | 3.23% | +9.1% |
| Q2 2020 | $3,022,000 | +13.6% | 17,091 | -11.1% | 2.96% | -1.2% |
| Q1 2020 | $2,661,000 | -7.2% | 19,222 | +2.9% | 3.00% | +21.7% |
| Q4 2019 | $2,867,000 | – | 18,677 | – | 2.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |